Advertisement

Community Experience With Intravenous Thrombolysis for Acute Stroke

  • Lama Al-Khoury
  • Christy M. Jackson
Part of the Current Clinical Neurology book series (CCNEU)

Abstract

The US Food and Drug Administration (FDA) approved intravenous tissue plasminogen activator (t-PA) as treatment for acute ischemic stroke in June 1996, based on the results of the National Institute of Neurological Disorders and Stroke (NINDS) study (see  Chapter 7). The next important question was whether t-PA treatment could be applied in nonstudy community medical centers with a feasibility, safety, and efficacy comparable to that of NINDS trial. This question was answered by many community studies, which evaluated t-PA therapy in acute ischemic stroke. This chapter discusses community experience with intravenous t-PA in stroke treatment from 1996 to the present. Those studies are discussed in chronological order, highlighting the outcome and complication rates of each. Table 1 summarizes the results.

Keywords

Acute Stroke Acute Ischemic Stroke Protocol Violation Intravenous Thrombolysis Acute Ischemic Stroke Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998; 29:18–22.PubMedGoogle Scholar
  2. 2.
    Grond M, Stenzel C, Schmulling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998; 29:1544–1549.PubMedGoogle Scholar
  3. 3.
    Tanne D, Bates V, Verro P, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. Neurology 1999; 53:424–427.PubMedGoogle Scholar
  4. 4.
    Egan R, Lutsep HL, Clark WM, et al. Open label tissue plasminogen activator for stroke: The Oregon experience. J Stroke Cerebrovasc Dis 1999; 8(5):287–290.PubMedCrossRefGoogle Scholar
  5. 5.
    Katzan I, Furlan A, Lloyd L, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283:1151–1158.PubMedCrossRefGoogle Scholar
  6. 6.
    Katzan I, Hammer M, Furlan A. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke. A Cleveland update. Stroke 2003; 34:799–800.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang D, Rose JA, Honings DR, Garwacki DJ, Milbrandt JC. Treating acute stroke patients with intravenous t-PA: the OSF Stroke Network experience. Stroke 2000; 31:77–81.PubMedGoogle Scholar
  8. 8.
    Albers GW, Bates V, Clark W, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283:1145–1150.PubMedCrossRefGoogle Scholar
  9. 9.
    Chapman KM, Woolfenden AR, Graeb D, et al. Intravenous tissue plasminogen activator for acute ischemic stroke. Stroke 2000; 31(12):2920–2924.PubMedGoogle Scholar
  10. 10.
    Barber PA, Zhang J, Demchuk A, Hill M, Buchan A. Why are stroke patients excluded from TPA therapy? Neurology 2001; 56:1015–1020.PubMedGoogle Scholar
  11. 11.
    Teal P, Hill MD, Buchan AM. Canadian Aactivase for Stroke Effectiveness Study (CASES). Available at http://www.thrombolysis-acute-stroke-therapy.org/pdf/78.pdf, 77. Accessed May 5, 2002.
  12. 12.
    Lopez-Yunez AM, Bruno A, Willliams LS, et al. Protocol violations in community-based rt-PA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001;32(12):16.Google Scholar
  13. 13.
    Hans-Christian Koennecke, Nohr R, Leistner S, Marx P. Intravenous tPA for ischemic stroke team. Performance over time, safety and efficacy in a single center-2-year experience. Stroke 1 A.D.; 32(5):1074–1078.Google Scholar
  14. 14.
    Grotta J, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke. Arch of Neurology 2001; 58(12):2009–2013.CrossRefGoogle Scholar
  15. 15.
    Trouillas P, et al. Thrombolysis with intravenous rt-PA in a series of 100 cases of acute carotid territory stroke. Stroke 1998; 29:2529–2540.PubMedGoogle Scholar
  16. 16.
    Trouillas P, Nighoghossian N, Derex L, Honnorat J. Prognosis at 5 years of acute cerebral infarcts of the carotid territory treated by intravenous rt-PA: data from the Lyon thrombolysis registry. Stroke 2002; 33(1):395. (Abstract)Google Scholar
  17. 17.
    Trouillas P, Nighoghosian N, Derex L, et al. Final Resultsof the Lyon rtPA Protocol (200 cases): Effect of intravenous rtPA within 7 hours without radiological and clinical exclusions in carotid territory acute cerebral infarcts. Letter, 2003.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Lama Al-Khoury
    • 1
  • Christy M. Jackson
    • 1
  1. 1.UCSD Stroke CenterSan Diego

Personalised recommendations